

Supplementary Information and Figures

New Ruthenium(II) Complexes with
Enantiomerically Pure Bis- and Tris(pinene)-
Fused tridentate ligands. Synthesis,
characterization and Stereoisomeric Analysis

Xavier Sala, Isabel Romero, Montserrat Rodríguez, Albert Poater, Antoni Llobet*,
Alexander von Zelewsky, Teodor Parella, Xavier Fontrodona, Miquel Solà*.*

Figure S1. X-ray structure and labeling scheme for the cationic part of complex **8a**. Hydrogen bonding interaction.




Table S1. Geometrical comparison between the X-ray data of isomer **4a** and the corresponding B3PW91 geometry (Distances in Å and angles in degrees).

Distances	dist(RX)	dist(B3LYP)	Angles	ang(RX)	ang(B3LYP)
Ru-N1	2.222	2.227	N3-Ru-N2	77.6	78.4
Ru-N2	2.173	2.187	N3-Ru-N1	81.0	79.7
Ru-N3	2.246	2.283	N2-Ru-N1	81.2	80.8
Ru-C11	2.454	2.448	N3-Ru-P1	176.3	176.5
Ru-P1	2.307	2.331	N2-Ru-P1	100.1	99.5
Ru-P2	2.320	2.351	N1-Ru-P1	95.8	97.2
P1-C13	1.850	1.864	N1-Ru-P2	178.4	177.4
P2-C14	1.847	1.860	N3-C43-C42	117.2	117.2
C13-C14	1.534	1.525	N2-Ru-P2	98.8	97.6
N2-C39	1.489	1.485	P1-Ru-P2	85.8	85.1
N2-C42	1.484	1.481	N3-Ru-C11	97.1	97.9
C39-C27	1.498	1.502	N1-Ru-C11	100.8	102.2
C42-C43	1.500	1.493	N2-Ru-C11	174.1	174.8
N1-C1	3.642	3.604	P1-Ru-C11	85.3	84.4
N3-C1	3.547	3.548	P2-Ru-C11	79.1	79.2
P1-C1	1.834	1.849	P1-C13-C14	111.1	110.4
P1-C7	1.852	1.859	P2-C14-C13	111.7	111.2
P2-C21	1.842	1.861	N2-C39-C27	115.8	114.8
P2-C15	1.837	1.844	N2-C42-C43	113.1	112.8
N2-C40	1.503	1.500	C1-P1-C7	99.2	99.5
C40-C41	1.532	1.528	C15-P2-C21	97.7	97.6

Figure S2. Relative energy diagram for the BP3W91-optimized geometries of the cationic moieties of complexes **8a-8d**.









Figure S3. NMR (500 MHz, 298 K, CD₂Cl₂) spectra for complex **3a**: (a) ¹H-NMR, (b) ¹³C-NMR, (c) NOESY (d) HMBC (e) HSQC.



(c)



(d)



(e)






Figure S4. NMR (500 MHz, 298 K, CD₂Cl₂) spectra for complex **4a**: (a) ¹H-NMR, (b) ³¹P-NMR, (c) NOESY (d) HMBC (e) HSQC (f) HMBC ¹H-³¹P



(a)





(b)



(c)





(f)






Figure S5. NMR (500 MHz, 298 K, CDCl₃) spectra for complex **5**: (a) ¹H-NMR, (b) ¹³C-NMR, (c) NOESY (d) HMBC (e) HSQC



(d)



(e)






Figure S6. NMR (500 MHz, 298 K, CDCl₃) spectra for complex **6**: (a) ¹H-NMR, (b) ³¹P-NMR, (c) NOESY (d) HMBC (e) HSQC (f) ¹H-³¹P HMBC


(a)




(b)




(c)



(d)



(e)



(f)




Figure S7. Cyclic Voltammetry ($\text{CH}_2\text{Cl}_2 + 0,1\text{M TBAP}$, 100 mV/s) of $[\text{Ru}(\text{L1 or L2})\text{Cl}_3]$ complexes. (a) $[\text{Ru}(\text{L1})\text{Cl}_3]$, **1**. (b) $[\text{Ru}(\text{L2})\text{Cl}_3]$, **2**.





Figure S8. Cyclic Voltammetry ($\text{CH}_2\text{Cl}_2 + 0,1\text{M TBAP}$, 100 mV/s) of *trans, fac* complexes. (a) *trans, fac*- $[\text{Ru}^{\text{II}}\text{Cl}(\text{L1})(\text{bpy})](\text{BF}_4)$, **3a**. (b) *trans, fac*- $[\text{Ru}^{\text{II}}\text{Cl}(\text{L1})(\text{dppe})](\text{BF}_4)$, **4a**.





Figure S9. Cyclic Voltammetry ($\text{CH}_2\text{Cl}_2 + 0,1\text{M TBAP}$, 100 mV/s) of complexes containing the **L2** ligand. (a) $[\text{Ru}^{\text{II}}\text{Cl}(\text{L2})(\text{bpy})](\text{BF}_4)$, **5** (b) $[\text{Ru}^{\text{II}}\text{Cl}(\text{L2})(\text{dppe})](\text{BF}_4)$, **6**.

